Original Articles: Asthma, Lower Airway DiseasesAsthma control during pregnancy and the risk of preterm delivery or impaired fetal growth
Section snippets
INTRODUCTION
Asthma is a chronic disorder that affects up to 8% of pregnant women in the United States. 1 Previous data suggest that women with asthma, especially severe asthma, have a higher rate of adverse perinatal outcomes, including preterm delivery and impaired fetal growth. 2 Intrauterine growth restriction (IUGR) and preterm delivery are common pregnancy complications that are associated with increased mortality and morbidity in the neonatal period and might have long-term consequences, such as
Study Population
Study participants were individuals enrolled in the multicenter, prospective study of Asthma Medication Use in Pregnancy conducted by the Organization of Teratology Information Specialists (OTIS) between February 1, 1998, and December 31, 2003. The methods of the study have been described elsewhere. 8, 13, 14 Briefly, 819 pregnant women with physician-diagnosed asthma were recruited through the OTIS counseling network in North America and were followed up through a central coordinating center
RESULTS
Among 719 women with asthma, 396 (56.3%) reported adequate control of asthma at their first maternal interview, whereas 308 (43.7%) reported fair to poor control of asthma, and 15 women had missing values for this variable (Table 1). At subsequent maternal interviews, a slightly smaller proportion of patients reported poor to fair control of their asthma (35.3% and 30.4%, respectively). During pregnancy 8.5% of patients were hospitalized for asthma and 21.3% had unscheduled asthma clinic visits.
DISCUSSION
In this study, poor maternal asthma symptom control early in pregnancy and a history of hospitalizations for asthma anytime during pregnancy were each associated with a doubling of the risk of preterm delivery independent of other risk factors. Increased risk of preterm delivery might be attributed to hypoxia secondary to severe and uncontrolled asthma or to an effect of asthma therapy during pregnancy: 2 factors that are often difficult to disentangle. Systemic corticosteroids are a class of
REFERENCES (33)
- et al.
Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys
Ann Epidemiol
(2003) - et al.
Asthma in pregnancy
Am J Med.
(2000) - et al.
Preterm delivery
Lancet
(2002) - et al.
Long-term metabolic consequences of being born small for gestational age
Semin Neonatol
(2004) - et al.
The relationship of asthma medication use to perinatal outcomes
J Allergy Clin Immunol
(2004) - et al.
Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies
Obstet Gynecol
(2003) - et al.
Severity of asthma and perinatal outcome
Am J Obstet Gynecol
(1992) - et al.
Asthma medication use in pregnancy and fetal growth
J Allergy Clin Immunol
(2005) The efficacy and safety of asthma medications during pregnancy
Semin Perinatol
(2001)- et al.
Cessation of asthma medication in early pregnancy
Am J Obstet Gynecol
(2006)
The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms
Immunol Allergy Clin North Am.
The Organization of Teratology Information Services (OTIS) Registry Study
J Allergy Clin Immunol
Safety of leukotriene receptor antagonists in pregnancy
J Allergy Clin Immunol
Twinning
Lancet
Development of the asthma control test: a survey for assessing asthma control
J Allergy Clin Immunol
Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth
J Allergy Clin Immunol
Cited by (78)
Management of asthma during pregnancy
2021, Revue des Maladies RespiratoiresOral Corticosteroids and Risk of Preterm Birth in the California Medicaid Program
2021, Journal of Allergy and Clinical Immunology: In PracticePerinatal Outcomes Associated with Maternal Asthma and Its Severity and Control During Pregnancy
2020, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Several studies have suggested an increased risk of adverse outcomes among pregnancies of women with asthma, including prematurity, intrauterine growth restriction, emergency cesarean delivery, and maternal mortality.1,3,5-14 However, other investigations have yielded contrasting results.8,9,11,15-17 Possible sources of heterogeneity in these findings include differences in the level of asthma severity and control across study populations and distinct focus on asthma diagnosis overall, severe asthma, or asthma exacerbations.
Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort
2020, Journal of Allergy and Clinical ImmunologyMaternal asthma severity and control during pregnancy and risk of offspring asthma
2018, Journal of Allergy and Clinical ImmunologyAmbient air pollution and low birth weight - are some women more vulnerable than others?
2017, Environment International
Disclosures: Dr Jones has consulting arrangements with Merck. Dr Chambers has consulting arrangements with Cephalom Pharmaceutical. Drs Jones and Chambers have received grant support from Sanofi-Aventis, Sanofi-Pasteur, Abbott Laboratories, Amgen, Apotex, Barr Laboratories, Kali Laboratories, Sandoz Pharmaceutical, Teva Pharmaceutical, and Bristol Myers Squibb. Dr Schatz has received grant support from GlaxoSmithKline and Sanofi-Aventis and has received honoraria from GlaxoSmithKlein, Genentech, and Merck. Dr Bakhireva has no conflict of interest.
Funding Sources: This research was supported by a grant from Aventis Pharmaceutical.
The following members of the OTIS Collaborative Research Group contributed to this study: Arizona Teratogen Information Program, University of Arizona, Tucson: D. Quinn, D. Vogt; California Pregnancy Risk Information, University of California, San Diego: K. Kao; Connecticut Pregnancy Exposure Information Service, University of Connecticut Health Center, Farmington: S. Lavigne, J. Brochu; Nebraska Teratogen Project, University of Nebraska Medical Center, Omaha: Dr B. Buehler, E. Conover; Illinois Teratogen Information Service, Chicago: K. Ormond, C. Chou; Michigan Teratogen Information Service, Children's Hospital of Michigan, Detroit: Dr Y. Johnson, S. Swerc; Missouri Teratogen Information Service, University of Missouri Hospital and Clinics, Columbia: Dr S. Braddock, P. Slusher; Pregnancy Risk Network, University of Buffalo: Dr L. Robinson, S. Gangell; Motherisk Program, Hospital for Sick Children, Toronto, Ontario: Dr G. Koren, M. Morreti; Texas Teratogen Information Service, University of North Texas, Denton: L. Wolfe; Pregnancy RiskLine Project, Utah Department of Health, Salt Lake City: Dr J. Carey; J. Robertson; CARE Northwest, University of Washington, Seattle: Dr J. Polifka, Dr E. Rudy.